formally known as gpha

Same medicine. Same results.
Lower cost.

GPhA and Biosimilars Council Applaud California Biosimilars Law

Contact: Steve Arnoff 202.249.7113 

WASHINGTON, DC (October 7, 2015) —The Generic Pharmaceutical Association (GPhA) and its Biosimilars Council applaud California for enacting a law to facilitate patient access to more affordable versions of biologic medicines.

“By enacting SB 671, Governor Jerry Brown and California legislators are demonstrating their commitment to both patient health and fiscal health in their state. This bill allows for substitution of interchangeable biologics and avoids measures that would hinder timely patient access to these products,” said Chip Davis, GPhA President and CEO.

In 2015, 11 states and Puerto Rico have passed legislation that facilitates interchangeable biologic substitution at the pharmacy. The first biosimilar was recently approved for use in the United States, and laws governing manufacturing, prescribing and dispensing are still being formed at the federal and state levels.

“With billions of dollars in health savings at stake for the nation’s patients, it is vital to make sure that the legal and regulatory framework enables competition and provides for timely access to safe, effective and more affordable therapies,” said Davis.

About GPhA
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 86 percent of the prescriptions dispensed in the U.S. but consume just 27 percent of the total drug spending. Additional information is available at Follow us on twitter: @gpha.

About the Biosimilars Council
The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at